CYTK - サイトキネティクス （Cytokinetics Incorporated） サイトキネティクスCYTKのチャート
CYTKの企業情報
| symbol | CYTK |
|---|---|
| 会社名 | Cytokinetics Inc （サイトキネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症（ALS）の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。 サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する｢Tirasemtiv(正式名称：CK-2017357)｣の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。 Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. |
| 本社所在地 | 280 East Grand Avenue South San Francisco CA 94080 USA |
| 代表者氏名 | Leonard Patrick Gage レナード・パトリック・ゲージ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-624-3000 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 137人 |
| url | www.cytokinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -112.14400 |
| 終値（lastsale） | 8.23 |
| 時価総額（marketcap） | 449588415.31 |
| 時価総額 | 時価総額（百万ドル） 429.92230 |
| 売上高 | 売上高（百万ドル） 17.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.34630 |
| 当期純利益 | 当期純利益（百万ドル） -130.64600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense). |
CYTKのテクニカル分析
CYTKのニュース
Cytokinetics Incorporated : Corporate Presentation August 2020 | MarketScreener 2020/08/18 15:35:10 MarketScreener
35/94 … | August 18, 2020
Cytokinetics Reports Second Quarter 2020 Financial Results 2020/08/06 20:00:00 GlobeNewswire
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Support…
Cytokinetics Incorporated : Corporate Presentation July 2020 | MarketScreener 2020/07/21 23:51:03 MarketScreener
35/94 … | July 22, 2020
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares 2020/07/21 20:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously…
Cytokinetics readies $150M stock offering (NASDAQ:CYTK) 2020/07/15 20:02:28 Seeking Alpha
Cytokinetics (NASDAQ:CYTK) initiates a $150M public offering of common stock. Price, volume and terms have yet to be announced.
Cytokinetics Reports First Quarter 2020 Financial Results 2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool 2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering 2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release 2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Reports First Quarter 2020 Financial Results 2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool 2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering 2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release 2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.